Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer
- John Hoff
- Lauren Baldwin
- Jason Lefringhouse
- Edward Pavlik
- Rachel Miller
- Christopher DeSimone
- Frederick Ueland
- Thomas Tucker
- Richard Kryscio
- J. R. van Nagell
DOIAbstract
Objective. The aim of this study was to document the survival advantage of lowering stage at detection from Stage IIIC to Stage IIIA epithelial ovarian cancer. Methods. Treatment outcomes and survival were evaluated in patients with Stage IIIA and Stage IIIC epithelial ovarian cancer treated from 2000 to 2009 at the University of Kentucky Markey Cancer Center (UKMCC) and SEER institutions. Results. Cytoreduction to no visible disease (P<0.0001) and complete response to platinum-based chemotherapy (P<0.025) occurred more frequently in Stage IIIA than in Stage IIIC cases. Time to progression was shorter in patients with Stage IIIC ovarian cancer (17±1 months) than in those with Stage II1A disease (36±8 months). Five-year overall survival (OS)...
Add to ORKG